LNCaP cells express androgen receptor and prostate-specific antigen, whereas PC3 cells do not, and thus they recapitulate features of androgen-sensitive and castration-resistant PCa, respectively (53); second, a few studies demonstrate that tumor suppressor p53 determines PCa cell sensitivity to chemotherapies (54–56). The gene discussed is TP53; the disease is posterior cortical atrophy.